Erlizumab Biosimilar - Research Grade

Human

ITGB2

>1mg/ml

Fab - G1 - kappa

CHO Cells

Bulk Anti-Human CD18 (IB4) Antibody (ICH1189)

https://www.imgt.org/mAb-DB/

ICH3002

P05107

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of erlizumab, supplied for research use only. Erlizumab (also known as rhuMAb CD18) is a humanized anti-CD18 antibody fragment directed against the integrin beta-2 subunit (ITGB2, UniProt P05107). The research-grade analog reproduces the antigen-binding specificity of the originator molecule as a Fab (human IgG1, kappa) format, without any therapeutic intent, and is not the clinical drug; it is not for human or veterinary use. It is useful as a target-specific binding and blocking reagent for in-vitro and preclinical work: as a positive/isotype-matched control in ITGB2 detection assays, for competitive binding and epitope studies, for interrogating leukocyte integrin function (adhesion, migration, activation), for neutralization and function-blocking experiments, and as reference material during antibody-engineering or assay-development pipelines. Because it is provided as a Fab, it lacks an Fc region and therefore does not mediate Fc-dependent effector functions, which can be advantageous when studying receptor engagement in isolation. The material is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support scale-up and reproducibility. ITGB2 (CD18, integrin beta-2, UniProt P05107) is the common beta subunit that pairs with distinct alpha chains to form the beta-2 (leukocyte) integrin family: LFA-1 (CD11a/CD18, alphaL beta2), Mac-1/CR3 (CD11b/CD18, alphaM beta2), p150,95/CR4 (CD11c/CD18, alphaX beta2), and CD11d/CD18. These heterodimers are expressed on leukocytes and mediate firm adhesion to endothelium, transendothelial migration, immune-synapse formation, phagocytosis, and complement-opsonized particle uptake. Key ligands include ICAM-1/2/3 and complement fragment iC3b. Beta-2 integrins undergo conformational activation ("inside-out" signaling) that switches them to high-affinity states, and they transmit "outside-in" signals upon ligand engagement. Loss-of-function mutations in ITGB2 cause leukocyte adhesion deficiency type I, characterized by impaired neutrophil recruitment and recurrent infections, underscoring the subunit's central role in leukocyte trafficking and innate immunity.

Cell surface adhesion glycoproteins LFA-1/CR3/p150 95 subunit beta, Complement receptor C3 subunit beta, Integrin beta-2, CD18, MFI7

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Erlizumab biosimilar available in bulk or gram quantities?

A: Yes — the Erlizumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Erlizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Erlizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Erlizumab that binds ITGB2.